US FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukaemia
My News Desk,
Approval of Lumoxiti, a first-in-class medicine for hairy cell leukaemia marks first new treatment option for patients in over…